TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00602082
Drug: streptozocin
Normalized name: Streptozocin
DrugBank: Streptozocin (DB00428)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04537286
Drug: nab-paclitaxel plus cisplatin plus carilizumab (AP+PD-1)
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nab-paclitaxel 125 mg/m2，ivgtt，d1, 8 Cisplatin 75 mg/m2，ivgtt，d1 Carilizumab 200mg, ivgtt，d1，q2w
Study: NCT00116610
Drug: picoplatin
Normalized name: Picoplatin
DrugBank: Picoplatin (DB04874)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00809718
Drug: Raltegravir and rifapentine
Normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Period 1- Raltegravir 400 mg q12h by mouth for 4 days~Period 2- Rifapentine 900 mg taken by mouth once per week for 3 doses and raltegravir 400 mg q12h by mouth for 4 days~Period 3- Rifapentine 600 mg taken by mouth once daily for 5 of 7 days per week for 10 doses and raltegravir 400 mg q12h by mouth for 4 days
Study: NCT02415413
Drug: carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02415413
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02415413
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02415413
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00309491
Drug: Tamoxifen alone
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 x 20 mg tamoxifen daily, start of therapy within 4 weeks after surgery; therapy duration 5 years
Study: NCT00309491
Drug: Tamoxifen + Aminoglutethimide
Normalized name: Aminoglutethimide
DrugBank: Aminoglutethimide (DB00357)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 x 20 mg tamoxifen daily (5 years) plus Aminoglutethimide daily (first 2 years)~* 1st therapy week:125mg/-/125mg Aminoglutethimide daily~* 2nd therapy week: 125mg/-/250mg Aminoglutethimid daily~* as of 3rd therapy week: 250mg/-/250mg Aminoglutethimid daily
Study: NCT02336529
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02336529
Drug: NaCl
Normalized name: NaCl
DrugBank: Linaclotide (DB08890)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00846976
Drug: Bicalutamide
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200mg daily
Study: NCT00364104
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous tartrate (DB13639)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6-weeks of iron supplementation only plus 10-days matching placebo of Hp infection eradication therapy
Study: NCT04626908
Drug: GC022F CAR-T cells
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject receive GC022F CAR-T cells by intravenous infusion
Study: NCT02132429
Drug: AMG 333
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration available in varying dose strength.
Study: NCT02644421
Drug: VVZ-149
Normalized name: Vvz-149 free base
DrugBank: Opiranserin (DB16271)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02644421
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00412919
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01671319
Drug: docetaxel + cyclophosphamide + pegfilgrastim
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: docetaxel 75 mg/m2 + cyclophosphamide 600 mg/m2 IV every 2 weeks x 4 cycles plus pegfilgrastim 6mg sq 24-48 hours post day 1 of each cycle
Study: NCT01628666
Drug: Conventional
Normalized name: PECTIN 11.5 mg in 7 g ORAL LOZENGE [Lolleez Birthday Cake - Conventional]
DrugBank: Pectin (DB11158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin preoperative
Study: NCT03053167
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan: 180mg/㎡+NS250ml, ivgtt, 90min, d1 Every 3 weeks
Study: NCT03053167
Drug: Raltitrexed
Normalized name: raltitrexed
DrugBank: Raltitrexed (DB00293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltitrexed: 3mg/㎡+NS100ml，ivgtt，15min, d1 Every 3 weeks
Study: NCT00510822
Drug: Cimicoxib
Normalized name: Cimicoxib
DrugBank: Cimicoxib (DB05095)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg per tablet, bid (total daily dose 100 mg)
Study: NCT00051545
Drug: Seocalcitol
Normalized name: Seocalcitol
DrugBank: Seocalcitol (DB04258)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00093704
Drug: bortezomib + ganciclovir
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8 and 11. Patients also receive ganciclovir IV twice daily on days 1-14. Treatment repeats every 21 days for a maximum of 3 courses.
Study: NCT01432730
Drug: Gefapixant
Normalized name: Gefapixant
DrugBank: Gefapixant (DB15097)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Oral tablets, BID
Study: NCT02311764
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin will be administered weekly
Study: NCT04052152
Drug: Anlotinib and Sintilimab injection
Normalized name: cytarabine and daunorubicin
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated with Anlotinib and Sintilimab injection
Study: NCT02383966
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants received Cetuximab as an intravenous infusion at an initial dose of 400 milligrams per square meter (mg/m\^2) on Day 1 and a subsequent dose of 250 mg/m\^2 on Day 8 and Day 15 of each 21-day treatment cycle.
Study: NCT02383966
Drug: Cisplatin/Carboplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin or Carboplatin (at an equivalent dose in case of intolerability of cisplatin) was administered at a dose of 75 mg/m\^2 as an intravenous infusion on Day 1 of each 21-day treatment cycle.
Study: NCT02383966
Drug: 5-fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants received 5-fluorouracil (FU) at a dose of 750 mg/m\^2/day as a continuous intravenous infusion over 24 hours a day from Day 1 to Day 5 of each 21-day treatment cycle.
Study: NCT04025736
Drug: Tranexamic Acid 100Mg/Ml Inj Vil 10Ml
Normalized name: TRANEXAMIC ACID 100MG/ML INJ VIL 10ML
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) is a synthetic analog of the amino acid lysine which acts by competitively blocking the plasminogen lysine-binding site and inhibiting fibrinolysis. Several studies showed that TXA could reduce both blood loss and the amount of blood transfusion after shoulder arthroplasty surgeries.
Study: NCT04025736
Drug: 0.9% Sodium Chloride Injection
Normalized name: SODIUM CHLORIDE 9 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [0.9% Sodium Chloride Injection, 500mL, DRE BioLab, TotalCare]
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Normal saline is a mixture of sodium chloride in water and has a number of uses in medicine. We use the same volume of normal saline as placebo.
Study: NCT02032433
Drug: Extended-Release Naltrexone
Normalized name: bupropion / naltrexone Extended Release Oral Tablet
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended-Release Naltrexone (Vivitrol®)
Study: NCT02032433
Drug: Buprenorphine-Naloxone
Normalized name: Buprenorphine-Naloxone
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine-Naloxone (Suboxone®)
Study: NCT00187005
Drug: Prednisone, Dexamethasone, Vincristine, Daunorubicin, PEG-L-asparaginase
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See Detailed Description section for details of treatment interventions.
Study: NCT02032394
Drug: Povidone-iodine
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15 ml 10%, 3 imes a day for 10 days /external use for Washing perinea area and catheter first 5 centimeters
Study: NCT02032394
Drug: Chlorhexidine
Normalized name: Chlorhexidine
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15 ml .2%, 3 imes a day for 10 days /external use for Washing perinea area and catheter first 5 centimeters
Study: NCT03315780
Drug: Dulaglutide
Normalized name: DULAGLUTIDE
DrugBank: Dulaglutide (DB09045)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered SC
Study: NCT03612869
Drug: LYS-SAF302
Normalized name: LYS-SAF302
DrugBank: Olenasufligene relduparvovec (DB16264)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment will involve direct injections of the investigational product into both sides of the brain through image-guided tracks, in a single neurosurgical session.
Study: NCT03881852
Drug: AXS-12 (Reboxetine)
Normalized name: AX
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosed orally, twice daily for up to 3 weeks
Study: NCT02262572
Drug: Telmisartan /HCTZ - compression tablet (DC)
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02262572
Drug: Telmisartan /HCTZ - dry granulation tablet (DG)
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02262572
Drug: Telmisartan /HCTZ - present commercial formulation
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01361308
Drug: Brisdelle (paroxetine mesylate)
Normalized name: Brisdelle
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo in a 1:1 ratio, administered once daily at bedtime beginning on Day 1 and continuing up to Day 84
Study: NCT00206700
Drug: Sargramostim (Leukine)
Normalized name: Sargramostim
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Open Label, 8 week cycle
Study: NCT01710007
Drug: Lipitor
Normalized name: Lipitor
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects should be instructed to take 1 capsule of study drug (1PC002 or atorvastatin) orally once a day, with or without food. Administration before bedtime or at regular time-interval is recommended.
Study: NCT03807856
Drug: Dabigatran Etexilate Mesylate
Normalized name: Dabigatran Etexilate Mesylate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran 150mg BID for 3 days
Study: NCT00462813
Drug: oral microencapsulated diindolylmethane
DrugBank: Methane (DB15994)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00003582
Drug: amifostine trihydrate
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01262196
Drug: MP4OX
Normalized name: Methoxsalen
DrugBank: Methoxsalen (DB00553)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4.3 g/dL pegylated hemoglobin in balanced lactate-electrolyte solution
Study: NCT01262196
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Normal saline (0.9%) solution
Study: NCT00707889
Drug: ABT-869
Normalized name: ABT-925
DrugBank: ABT-639 (DB15055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg QD, tablets taken orally days 1-14 of every 14-day cycle
Study: NCT00707889
Drug: bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 mg/kg QD, IV on Day 1 of each 14-day cycle
Study: NCT00707889
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 85 mg/m2 IV, 120 minutes on Day 1 of each 14-day cycle
Study: NCT00003582
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00707889
Drug: folinic acid
Normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m2 IV, 120 minutes on Day 1 of each 14-day cycle
Study: NCT00707889
Drug: ABT-869
Normalized name: ABT-925
DrugBank: ABT-639 (DB15055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg QD tablets taken orally days 1-14 of every 14-day cycle
Study: NCT03537404
Drug: Narlaprevir
Normalized name: narlaprevir
DrugBank: Narlaprevir (DB14760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg, film-coated tablets, taken as 200 mg per os daily
Study: NCT03537404
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100 mg, film-coated tablets, taken as 100 mg per os daily
Study: NCT03537404
Drug: Tenofovir Disoproxil Fumarate
Normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 mg, film-coated tablets, taken as 300 mg per os daily
Study: NCT03537404
Drug: Raltegravir
Normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 400 mg, film-coated tablets, taken as 400 mg per os daily
Study: NCT00003582
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00090207
Drug: MK0869, aprepitant / Duration of Treatment: 3 days
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00090207
Drug: Comparator: ondansetron / Duration of Treatment: 4 days
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00248040
Drug: Reparixin continuous infusion
Normalized name: Ivy Dry Super Continuous Spray
DrugBank: Reparixin (DB12614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Investigational Product was administered as an intravenous infusion into a (high flow) central vein or through an arterio-venous fistula, by an infusion pump adequate to provide reliable infusion rates, as per treatment schedule. Total infusion volume did not exceed 500 mL/24 hours. A dose of 2.772 mg/kg body weight/hour was to be administered for 12 hours. Placebo was volume/schedule matched saline.
Study: NCT00248040
Drug: reparixin intermittent infusion
Normalized name: Duo Fusion
DrugBank: Reparixin (DB12614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A dose of 2.244 mg/kg body weight was to be administered over a 30-minute period, followed by a 1.5-hour interval. Twelve doses were to be administered over a total period of 22.5 hours. Placebo was volume/schedule matched saline.
Study: NCT03387085
Drug: Aldoxorubicin HCl
Normalized name: Doxorubicin Hydrochloride
DrugBank: Aldoxorubicin (DB06013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldoxorubicin hydrochloride
Study: NCT00681876
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan (IV) 150 mg/m2 on day 1 every two weeks until progression
Study: NCT00681876
Drug: Avastin
Normalized name: Avastin
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avastin (IV) 10 mgr/Kgr on day 1 every 2 weeks until progression
Study: NCT00681876
Drug: Erbitux
Normalized name: Erbitux
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Erbitux (IV)500 mg/m2 on day 1 every two weeks until progression
Study: NCT03387085
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cis-diamminedichloroplatinum(II)
Study: NCT03387085
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione
Study: NCT03387085
Drug: nab-Paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
Study: NCT01165892
Drug: Gadofosveset Triodium
Normalized name: Gadofosveset Trisodium
DrugBank: Gadofosveset trisodium (DB06705)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of 0.03 mmol/Kg of gadofosveset trisodium (Ablavar)once with intravascular half life of up to 1 hr and optimal arterial imaging out to 20-30 minutes.
Study: NCT00482976
Drug: Ruboxistaurin
Normalized name: RUBOXISTAURIN
DrugBank: Ruboxistaurin (DB11829)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02965027
Drug: Prazosin
Normalized name: Prazosin
DrugBank: Prazosin (DB00457)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02698553
Drug: Bupropion HCl XL tablet 150mg
Normalized name: bupropion hydrochloride Oral Tablet
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The 150 mg of tablet will be given to subject once daily orally. Subject will be instructed to swallow whole tablet with 240 ml of water, without crushed, divided or chewed.
Study: NCT02698553
Drug: Bupropion HCl XL tablet 300mg
Normalized name: bupropion hydrochloride Oral Tablet
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The 300 mg of tablet will be given to subject once daily orally. Subject will be instructed to swallow whole tablet with 240 ml of water, without crushed, divided or chewed.
Study: NCT01177397
Drug: CC-223
Normalized name: glycerin 0.223 MG/MG
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: (closed to enrollment) Dose level starts with 7.5mg daily taken by mouth in cycles of 28 days. Level increases for different patient cohorts in 100% or 50% increments until optimal dose level is established for further study. Treatment continues for as long as patient benefits (i.e., until disease progression or unacceptable toxicity). Part B: (closed to enrollment) Optimal dose is administered in 28 day cycles until disease progression.
Study: NCT00193271
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00193271
Drug: Estramustine
Normalized name: Estramustine
DrugBank: Estramustine (DB01196)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02905227
Drug: CVT-427 (zolmitriptan inhalation powder)
Normalized name: zolmitriptan Inhalant Product
DrugBank: Zolmitriptan (DB00315)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each subject received 2 self-administered doses of 3.0 mg CVT-427 (zolmitriptan inhalation powder), 2 hours apart.
Study: NCT00354432
Drug: Venlafaxine
Normalized name: Venlafaxine
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients receive oral venlafaxine 75mg.
Study: NCT01977989
Drug: Vancomycin Powder
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For surgeries involving 3 contiguous spinal segments or less, 500mg of vancomycin will be applied topically. For surgeries involving more than 3 contiguous spinal segments, 1gm of vancomycin will be applied topically to the surgical site.
Study: NCT02739061
Drug: sertraline, fluvoxamine
DrugBank: Fluvoxamine (DB00176)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Select specified drugs (sertraline, fluvoxamine)
Study: NCT00329589
Drug: Velcade (bortezomib)
Normalized name: Velcade
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01818011
Drug: GSK1322322 over granulated tablets
Normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light beige, oval shaped, film-coated tablet with unit dose strength of 500 mg/tablet and dose level of 1500 mg (3 x 500 mg) for single dose oral administration in Part A
Study: NCT01818011
Drug: GSK1322322 intended commercial tablets
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Light beige, oval shaped, film-coated tablet with unit dose strength of 500 mg/tablet and dose level of 1000 mg (2 x 500),1500 mg (3 x 500 mg) and 2000 mg (4 x 500mg) for single dose oral administration in Part A and B and repeat dose administration twice daily in Part C
Study: NCT01818011
Drug: 13C-GSK1322322 stable isotope powder
Normalized name: 13C-urea
DrugBank: Urea C-13 (DB09510)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: White to slightly colored non-sterile crystalline powder for oral suspension with dose level of 50 mg as a single dose with GSK1322322 tablets in Part A
Study: NCT03218657
Drug: levamisole hydrochloride
Normalized name: Levamisole Hydrochloride
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: levamisole hydrochloride take orally 150mg qod
Study: NCT03218657
Drug: Cyclosporins
Normalized name: Cyclosporine
DrugBank: Cyclo(his-pro) (DB02414)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporines take orally 3-5mg/kg\*d qd
Study: NCT00588835
Drug: aprepitant
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 125mg on Day 1; 80mg on Day 2-3 during CE cycle. Dexamethasone is added as well.
Study: NCT00588835
Drug: Dexamethasone and Ondansetron during CE-treatment
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard anti-emetic regimen during CE treatment
Study: NCT00785785
Drug: Nilotinib (AMN107)
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00785785
Drug: imatinib (STI571)
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04522544
Drug: Tremelimumab
Normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg Tremelimumab C1D1
Study: NCT04522544
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1500 mg Durvalumab C1D1 + Q4W (max. 13 cycles)
Study: NCT04527770
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ultrasound guided median nerve hydrodiseection using dexamethasone or midazolam
Study: NCT04527770
Drug: Midazolam injection
Normalized name: midazolam Injection
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intracarpal injection of midazolam and bupivacaine 0.5%
Study: NCT02087865
Drug: donepezil HCL
Normalized name: donepezil HCl
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no